Study design
PD
This proof‐of‐concept, randomized, double‐blind, three‐arm, placebo‐controlled, Phase 2a trial was performed to evaluate the safety, tolerability, PK, pharmacodynamics (PD), and preliminary efficacy of batoclimab in patients with anti‐AChR antibody‐positive gMG (Schematic design and patient flow for the double‐blind Phase 2a trial with OLE. OLE, open‐label extension; q2w, once every 2 weeks; qw, once weekly; R, randomization. 